Антагонисты окситоциновых рецепторов и их клиническое применение

Авторы:
  • В. И. Циркин
    ФГБОУ ВО «Вятский государственный университет», Киров, Россия; ФГБОУ ВО «Казанский государственный медицинский университет», Казань, Россия
  • С. И. Трухина
    ФГБОУ ВО «Вятский государственный университет», Киров, Россия
  • А. Н. Трухин
    ФГБОУ ВО «Вятский государственный университет», Киров, Россия
  • С. В. Хлыбова
    ФГБОУ ВО «Кировский государственный медицинский университет», Киров, Россия
  • К. Ю. Анисимов
    ФГБОУ ВО «Уральский государственный медицинский университет», Екатеринбург, Россия
Журнал: Российский вестник акушера-гинеколога. 2018;18(5): 16-22
Просмотрено: 945 Скачано: 16
Обзор касается описания блокаторов окситоциновых рецепторов, которые могут быть использованы для торможения сократительной деятельности матки при преждевременных родах (ПР), экстракорпоральном оплодотворении (ЭКО) и для остановки родового процесса в интересах плода. Главным образом представлены сведения о пептидном блокаторе окситоциновых рецепторов атозибана, который разрешен к применению в Европе, США и России. Имеющиеся данные свидетельствуют об эффективности атозибана как токолитика при указанных акушерских ситуациях и об его относительно высокой безопасности для матери и плода. Обзор также содержит сведения о блокаторах окситоциновых рецепторов, проходящих предклинические испытания (пептидный блокатор барусибан, непептидные блокаторы типа ретозибана и др.).
Ключевые слова:
  • окситоцин
  • окситоциновые рецепторы
  • роды
  • преждевременные роды
  • токолитики
  • пептидные (атозибан
  • барусибан) и непептидные (ретозибан) антагонисты окситоциновых рецепторов

КАК ЦИТИРОВАТЬ:

Циркин В.И., Трухина С.И., Трухин А.Н., Хлыбова С.В., Анисимов К.Ю. Антагонисты окситоциновых рецепторов и их клиническое применение. Российский вестник акушера-гинеколога. 2018;18(5):16-22. https://doi.org/10.17116/rosakush20181805116

Список литературы:

  1. Акушерство: Национальное руководство. Под ред. Айламазяна Э.К., Кулакова В.И., Радзинского В.Е., Савельевой Г.М. М.: ГЭОТАР-Медиа. 2009; 1218.
  2. Vrachnis N, Malamas FM, Sifakis S, Deligeoroglou E, Iliodromiti Z. The oxytocin — oxytocin receptor system and its antagonists as tocolytic agents. International Journal of Endocrinology. 2011;2011:art 350546. PMID: 22190926 PMCID: PMC3235456 https://doi.org/10.1155/2011/350546
  3. Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. Journal of Neuroendocrinology. 2014;26:6:356-369. PMID: 24888645 https://doi.org/10.1111/jne.12154
  4. Alotaibi MF. The response of rat and human uterus to oxytocin from different gestational stages in vitro. General Physiology and Biophysics. 2017;36:1:75-82. PMID: 27787232. https://doi.org/10.4149/gpb_2016022
  5. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews. 2001;81:2:629-683. PMID: 11274341 https://doi.org/10.1152/physrev.2001.81.2.629
  6. Kimura T, Ogita K, Kumasawa K, Tomimatsu T, Tsutsui T. Molecular analysis of parturition via oxytocin receptor expression. Taiwanese Journal of Obstetrics and Gynecology. 2013;52:2:165-170. PMID: 23915847 https://doi.org/10.1016/j.tjog.2013.04.004
  7. Yulia A, Johnson MR. Myometrial oxytocin receptor expression and intracellular pathways. Minerva Ginecologica. 2014;66:3:267-280. PMID: 24971782
  8. Szukiewicz D, Bilska A, Mittal TK, Stangret A, Wejman J, Szewczyk G, Pyzlak M, Zamlynski J. Myometrial contractility influences oxytocin receptor (OXTR) expression in term trophoblast cells obtained from the maternal surface of the human placenta. BMC Pregnancy and Childbirth. 2015;15:220. PMID: 26377392 https://doi.org/10.1186/s12884-015-0656-3
  9. Arthur P, Taggart MJ, Mitchell BF. Oxytocin and parturition: a role for increased myometrial calcium and calcium sensitization? Frontiers in Bioscience. 2007;12:619-633. PMID: 17127323 https://doi.org/10.2741/2087
  10. Kim SH, MacIntyre DA, Hanyaloglu AC, Blanks AM, Thornton S, Bennett PR, Terzidou V. The oxytocin receptor antagonist, Atosiban, activates pro-inflammatory pathways in human amnion via G(αi) signalling. Molecular and Cellular Endocrinology. 2016;420:11-23. PMID: 26586210 https://doi.org/10.1016/j.mce.2015.11.012
  11. Gram A, Boos A, Kowalewski MP. Uterine and placental expression of canine oxytocin receptor during pregnancy and normal and induced parturition. Reproduction in Domestic Animals. 2014;49:Suppl 2:41-49. PMID: 24947860 https://doi.org/10.1111/rda.12295
  12. Friebe-Hoffmann U, Baston DM, Hoffmann TK, Chiao JP, Rauk PN. The influence of interleukin-1beta on oxytocin signalling in primary cells of human decidua. Regulatory Peptides. 2007;142:3:78-85. PMID: 17428554 https://doi.org/10.1016/j.regpep.2007.01.012
  13. Fuchs AR, Goeschen K, Husslein P, Rasmussen AB, Fuchs F. Oxytocin and initiation of human parturition. III. Plasma concentrations of oxytocin and 13,14-dihydro-15-keto-prostaglandin F2 alpha in spontaneous and oxytocin-induced labor at term. American Journal of Obstetrics and Gynecology. 1983;147:5:497-502. PMID: 6638091 https://doi.org/10.1016/0002-9378(83)90005-4
  14. Mesiano S, Chan EC, Fitter JT, Kwek K, Yeo G, Smith R. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. The Journal of Clinical Endocrinology & Metabolism. 2002;87:6:2924-2930. PMID: 12050275 https://doi.org/10.1210/jcem.87.6.8609
  15. Bishop C.V. Progesterone inhibition of oxytocin signaling in endometrium. Frontiers in Neuroscience. 2013;7:art. 138. PMID: 23966904 PMCID: PMC3735988 https://doi.org/10.3389/fnins.2013.00138
  16. Renthal NE, Williams KC, Mendelson CR. MicroRNAs–mediators of myometrial contractility during pregnancy and labour. Nature Reviews Endocrinology. 2013;9:7:391-401. PMID: 23669656 https://doi.org/10.1038/nrendo.2013.96
  17. Mendelson CR. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Molecular Endocrinology. 2009;23:7:947-954. PMID: 19282364 https://doi.org/10.1210/me.2009-0016
  18. Thota C, Farmer T, Garfield R, Menon R, Al-Hendy A. Vitamin D elicits anti-inflammatory response, inhibits contractile-associated proteins, and modulates Toll-like receptors in human myometrial cells. Reproductive Sciences. 2013;20:4:463-475. PMID: 23012315 https://doi.org/10.1177/1933719112459225
  19. Ivanisević M, Djelmis J, Buković D. Review on prostaglandin and oxytocin activity in preterm labor. Collegium antropologicum. 2001;25:2:687-694. PMID:11811300
  20. Phaneuf S, Europe-Finner GN, Carrasco MP, Hamilton CH, López Bernal A. Oxytocin signalling in human myometrium. Advances in Experimental Medicine and Biology. 1995;395:453-467. PMID: 8713998
  21. Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews. 2014;6:art. CD004452. PMID: 24903678 https://doi.org/10.1002/14651858.CD004452. pub3
  22. van Vliet EO, Boormans EM, de Lange TS, Mol BW, Oudijk MA. Preterm labor: current pharmacotherapy options for tocolysis. Expert Opinion on Pharmacotherapy. 2014;15:6:787-797. PMID: 24533566 https://doi.org/10.1517/14656566.2014.889684
  23. Haram K, Mortensen JH, Morrison JC. Tocolysis for acute preterm labor: does anything work. The Journal of Maternal-Fetal & Neonatal Medicine. 2015;28:4:371-378. PMID: 24990666 https://doi.org/10.3109/14767058.2014.918095
  24. Rozenberg Р. Le point sur la tocolyse [A review on tocolysis]. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2015;44:8:752-759. PMID: 26142210 https://doi.org/10.1016/j.jgyn.2015.06.015
  25. Lamont CD, Jørgensen JS, Lamont RF. The safety of tocolytics used for the inhibition of preterm labour. Expert Opinion on Drug Safety. 2016;15:9:1163-1173. PMID: 27159501 https://doi.org/10.1080/14740338.2016.1187128
  26. van Vliet EO, Nijman TA, Schuit E, Heida KY, Opmeer BC, Kok M, Gyselaers W, Porath MM, Woiski M, Bax CJ, Bloemenkamp KW, Scheepers HC, Jacquemyn Y, van Beek E, Duvekot JJ, Franssen MT, Papatsonis DN, Kok JH, van der Post JA, Franx A, Mol BW, Oudijk MA. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. The Lancet. 2016;387(10033):2117-2124. PMID: 26944026 https://doi.org/10.1016/S0140-6736(16)00548-1
  27. Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour. Drugs. 2004;64:4:375-382. PMID: 14969573 https://doi.org/10.2165/00003495-200464040-00003
  28. Jenkin G. Oxytocin and prostaglandin interactions in pregnancy and at parturition. Journal of Reproduction and Fertility. Supplement. 1992;45:97-111. PMID: 1304035
  29. Pettibone DJ, Guidotti M, Harrell CM, Jasper JR, Lis EV, O’Brien JA, Reiss DR, Woyden CJ, Bock MG, Evans BE. Progress in the development of oxytocin antagonists for use in preterm labor. Advances in Experimental Medicine and Biology. 1995;395:601-612. PMID: 8714024
  30. Douglas AJ, Leng G, Russell JA. The importance of oxytocin mechanisms in the control of mouse parturition. Reproduction. 2002;123: 4:543-552. PMID: 11914117 https://doi.org/10.1530/rep.0.1230543
  31. Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, Steinwall M. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. British Journal of Obstetrics and Gynaecology. 1999;106:10:1047-1053. PMID:10519430 https://doi.org/10.1111/j.1471-0528.1999.tb08112.x
  32. Bossmar T. Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Journal of Perinatal Medicine. 1998; 26:6:458-465. PMID: 10224602. https://doi.org/10.1515/jpme.1998.26.6.458
  33. Thornton S, Vatish M, Slater D. Oxytocin antagonists: clinical and scientific considerations. Experimental Physiology. 2001;86:2:297-302. PMID: 11429647. https://doi.org/10.1113/eph8602186
  34. Pierzynski P. Oxytocin and vasopressin V1A receptors as new therapeutic targets in assisted reproduction. Reproductive BioMedicine Online. 2011;22:1:9-16. PMID: 21130036. https://doi.org/10.1016/j.rbmo.2010.09.015
  35. Yamashita K, Kitano T. Molecular evolution of the oxytocin-oxytocin receptor system in eutherians. Molecular Phylogenetics and Evolution. 2013;67:2:520-528. PMID: 23485918. https://doi.org/10.1016/j.ympev.2013.02.017
  36. Akerlund M, Strömberg P, Hauksson A, Andersen LF, Lyndrup J, Trojnar J, Melin P. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. British Journal of Obstetrics and Gynaecology. 1987;94:11:1040-1044. PMID: 3322368 https://doi.org/10.1111/j.1471-0528.1987.tb02287.x
  37. Arrowsmith S, Neilson J, Wray S. The combination tocolytic effect of MgSO4 and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. American Journal of Obstetrics and Gynecology. 2016;215:6:789.e1-789.e9. PMID: 27555315 https://doi.org/10.1016/j.ajog.2016.08.015
  38. Carvajal JA, Zambrano MJ, Theodor NM, Moreno LE, Olguín TR, Vanhauwaert PS, Rojas NB, Delpiano AM. The synergic in vitro tocolytic effect of nifedipine plus ritodrine on human myometrial contractility. Reproductive Sciences. 2017;24:4:635-640. PMID: 27609401 https://doi.org/10.1177/1933719116667221
  39. Engstrom T, Bratholm P, Christensen NJ, Vilhardt H. Up-regulation of oxytocin receptors in non-pregnant rat myometrium by isoproterenol: effects of steroids. Journal of Endocrinology. 1999;161: 3:403-411. PMID: 10333543 https://doi.org/10.1677/joe.0.1610403
  40. Schmitz T, Cabrol D. Tocolysis. Atosiban, an ocytcin-receptor antagonist. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2001;30:3:238-245. PMID: 11397999
  41. López Bernal A. Mechanisms of labour-biochemical aspects. BJOG: An International Journal of Obstetrics & Gynaecology. 2003;110:Suppl 20:39-45. PMID:12763110 https://doi.org/10.1046/j.1471-0528.2003.00023.x
  42. de Heus R, Mulder EJ, Derks JB, Visser GH. Acute tocolysis for uterine activity reduction in term labor: a review. Obstetrical & Gynecological Survey. 2008;63:6:383-388. PMID: 18492294 https://doi.org/10.1097/OGX.b013e31816ff75b
  43. Zingg HH. Vasopressin and oxytocin receptors. Baillière’s Clinical Endocrinology and Metabolism. 1996;10:1:75-96. PMID: 8734452 https://doi.org/10.1016/s0950-351x(96)80314-4
  44. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstetrics & Gynecology. 1999; 94:5:Pt 2:869-877. PMID: 10546776 https://doi.org/10.1097/00006250-199911001-00043
  45. Coomarasamy A, Knox EM, Gee H, Song F, Khan KS. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a metaanalysis with an indirect comparison of randomised trials. BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110:12:1045-1049. PMID: 14664874 https://doi.org/10.1111/j.1471-0528.2003.03071.x
  46. Kashanian M, Akbarian AR, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology & Obstetrics. 2005;91:1:10-14. PMID: 16043178 https://doi.org/10.1016/j.ijgo.2005.06.005
  47. Thornton JG. Maintenance tocolysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2005;112:Suppl 1:118-121. PMID: 15715609 https://doi.org/10.1111/j.1471-0528.2005.00599.x
  48. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database of Systematic Reviews. 2005;3:art. CD004452. PMID: 16034931 https://doi.org/10.1002/14651858.cd004452.pub2
  49. Giles W, Bisits A. Preterm labour. The present and future of tocolysis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2007;21:5:857-868. PMID: 17459777 https://doi.org/10.1016/j.bpobgyn.2007.03.011
  50. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. British Medical Journal. 2012;345:art. e6226. PMID: 23048010 https://doi.org/10.1136/bmj.e6226
  51. Gáspár R, Hajagos-Tóth J. Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations. Pharmaceuticals (Basel). 2013;23:6:689-699. PMID:24276256 https://doi.org/10.3390/ph6060689
  52. Caritis S. Adverse effects of tocolytic therapy. BJOG: An International Journal of Obstetrics & Gynaecology. 2005;112:Suppl 1:74-78. PMID:15715600 https://doi.org/10.1111/j.1471-0528.2005.00590.x
  53. Areia A, Fonseca E, Moura P. Progesterone use after successful treatment of threatened pre-term delivery. Journal of Obstetrics and Gynaecology. 2013;33:7:678-681. PMID: 24127952 https://doi.org/10.3109/01443615.2013.820266
  54. Циркин В.И., Колпаков А.Г. Влияние атозибана на ингибирующий эффект адреналина в опытах с миометрием небеременных крыс. Биодиагностика состояния природных и природно-техногенных систем: Материалы ХV Всероссийской научно-практической конференции с международным участием, 4-6 декабря 2017 г. Книга 1. Киров. 2017;284-289.
  55. Циркин В.И., Анисимов К.Ю., Хлыбова С.В. Бета-адренорецепторный ингибирующий механизм и его роль в регуляции сократительной деятельности матки беременных женщин и рожениц (обзор литературы). Уральский медицинский журнал. 2014;4:5-14.
  56. Nilsson L, Reinheimer T, Steinwall M, Akerlund M. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110:11:1025-1028. PMID: 14592588 https://doi.org/10.1111/j.1471-0528.2003.02540.x
  57. Pierzynski P, Lemancewicz A, Reinheimer T, Akerlund M, Laudanski T. Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women. Journal of the Society for Gynecologic Investigation. 2004;11:6:384-387. P MID: 15350251 https://doi.org/10.1016/j.jsgi.2004.02.008
  58. Reinheimer TM, Chellman GJ, Resendez JC, Meyer JK, Bee WH. Barusiban, an effective long-term treatment of oxytocin-induced preterm labor in nonhuman primates. Biology of Reproduction. 2006;75:5:809-814. PMID: 16914691 https://doi.org/10.1095/biolreprod.106.053637
  59. Steinwall M, Bossmar T, Brouard R, Laudanski T, Olofsson P, Urban R, Wolff K, Le-Fur G, Akerlund M. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecological Endocrinology. 2005;20:2:104-109. PMID: 15823830 https://doi.org/10.1080/09513590400021144
  60. Thornton S, Goodwin TM, Greisen G, Hedegaard M, Arce JC. The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. American Journal of Obstetrics and Gynecology. 2009;200:6:627.e1-e610. PMID: 19306963 https://doi.org/10.1016/j.ajog.2009.01.015
  61. Reinheimer TM, Bee WH, Resendez JC, Meyer JK, Haluska GJ, Chellman GJ. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. The Journal of Clinical Endocrinology & Metabolism. 2005;90:4:2275-2281. PMID: 15671092 https://doi.org/10.1210/jc.2004-2120
  62. Brouard R, Bossmar T, Fournié-Lloret D, Chassard D, Akerlund M. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG: An International Journal of Obstetrics and Gynaecology. 2000; 107:5:614-619. PMID: 10826575 https://doi.org/10.1111/j.1471-0528.2000.tb13302.x
  63. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. Journal of Neuroendocrinology. 2012;24:4:609-628. PMID: 22375852 PMCID: PMC3490377 https://doi.org/10.1111/j.1365-2826.2012.02303.x
  64. Boccia ML, Gorsaud AP, Bachevalier J, Anderson KD, Pedersen CA. Peripherally administered non-peptide oxytocin antagonist, L368,899, accumulates in limbic brain areas: a new pharmacological tool for the study of social motivation in non-human primates. Hormones and Behavior. 2007;52:3:344-351. PMID: 17583705 https://doi.org/10.1016/j.yhbeh.2007.05.009
  65. McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2007;293:1:R299-R305. PMID: 17395790 https://doi.org/10.1152/ajpregu.00057.2007
  66. Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-yridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. Journal of Pharmacology and Experimental Therapeutics. 2004;309:1:414-424. PMID: 14722330 https://doi.org/10.1124/jpet.103.061200